PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Thromb Haemost 2024; 124(07): 669-675
DOI: 10.1055/a-2239-9265
New Technologies, Diagnostic Tools and Drugs

DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study

Autoren

  • Adrián Segura-Díaz   *

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

  • Ruth Stuckey   *

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

  • Yanira Florido

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

  • Marta Sobas

    2   Department of Hematology and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland

  • Alberto Álvarez-Larrán

    3   Hematology Department, Hospital Clínic, Barcelona, Spain

  • Francisca Ferrer-Marín

    4   Hematology Department, Hospital Morales Messeguer, Instituto Murciano de Investigación Biosanitaria, Centro de Investigación Biomédica en Red de Enfermedades Raras, Universidad Católica San Antonio de Murcia, Murcia, Spain

  • Manuel Pérez-Encinas

    5   Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain

  • Gonzalo Carreño-Tarragona

    6   Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

  • María L. Fox

    7   Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain

  • Barbara Tazón Vega

    7   Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain

  • Beatriz Cuevas

    8   Hematology Department, Hospital Universitario de Burgos, Burgos, Spain

  • Juan F. López Rodríguez

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

  • Nuria Sánchez-Farías

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

  • Jesús M. González-Martín

    9   Investigation Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain

  • María T. Gómez-Casares

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
    10   Department of Medical Sciences, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain

  • Cristina Bilbao-Sieyro

    1   Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
    11   Morphology Department, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain
    • on behalf of the Spanish MPN Group (GEMFIN)

Funding This study was supported by funding from the Fundación DISA.
Weitere Informationen
  Lizenzen und Reprints


Graphical Abstract

Abstract

Background Polycythemia vera (PV) patients are classified as high or low thrombotic risk based on age and prior history of thrombosis. Despite adherence to treatment recommendations, vascular events remain frequent, leading us to question whether thrombotic risk stratification could be improved. We previously reported an association between thrombotic events and mutations in DTA genes (DNMT3A, TET2, and ASXL1). The objective of this study was to confirm this observation in a larger series of PV patients.

Methods PV patients with a minimum follow-up of 3 years were recruited from 8 European centers. Medical history was searched for thrombotic event recorded at any time and next-generation sequencing carried out with a myeloid panel. Multivariable logistic regression evaluated the impact of variables on thrombotic risk. Kaplan–Meier thrombosis-free survival curves were compared by the log rank test. Associations in the total cohort were confirmed in a case–control study to exclude selection bias.

Results Of the 136 patients recruited, 74 (56.1%) had a thrombotic event, with an incidence density of 2.83/100 person-years. In multivariable analysis, DTA mutation was a risk factor for thrombotic event, being predictive for shorter thrombosis-free survival in the whole cohort (p = 0.007), as well as in low-risk patients (p = 0.039) and older patients (p = 0.009), but not for patients with a prediagnostic event. A gender- and age-matched case–control study confirmed the increased risk of thrombotic event for PV patients with a DTA mutation.

Conclusion Our results support the use of molecular testing at diagnosis to help predict which PV patients are at higher risk of developing thrombosis.

Keywords

myeloproliferative neoplasm - cardiovascular event - next-generation sequencing - prognosis - CHIP

Ethical Approval Statement

This retrospective noninterventional study was approved by our Institutional Review Board (Comité Ético de Investigación Clínica, ref. 2019-230-1) on March 28, 2019 and conducted in accordance with the Declaration of Helsinki. All patient data were dissociated and anonymized; informed consent was not required due to the retrospective nature of the study and because the results did not affect the clinical management of patients.


Data Availability Statement

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.


Authors' Contribution

A.S.D. contributed data, curated data, analyzed the data, and wrote the paper; R.S. coordinated the study, curated data, analyzed the data, performed statistical analysis, and wrote the paper; Y.F. performed next-generation sequencing; M.S., A.A.L., F.F.M., M.P.E., G.C.T., M.L.F., B.T.V., and B.C. contributed data, J.F.L.R. and N.F.S. curated data; J.M.G.M. performed statistical analysis; M.T.G.C. designed the research study; C.B.S. designed the research study, performed statistical analysis and wrote the paper. All authors read and approved the final version of the manuscript.


* These authors contributed equally to this work.


Supplementary Material



Publikationsverlauf

Eingereicht: 11. September 2023

Angenommen: 23. Dezember 2023

Accepted Manuscript online:
08. Januar 2024

Artikel online veröffentlicht:
30. Januar 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany